Acumen’s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS)
· seekingalpha.com
ABOS outlook: sabirnetug and the ALTITUDE-AD Phase 2 readout are key to 2026 upside.
Acumen Pharmaceuticals, Inc. ( ABOS ) is a clinical-stage biotech built around sabirnetug (ACU193), an Alzheimer's antibody candidate designed to selectively ta...